Clinical Trials Logo

Coronary Aneurysm clinical trials

View clinical trials related to Coronary Aneurysm.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06220682 Completed - Clinical trials for Coronary Artery Ectasia

Endothelial NO Synthase Polymorphic Gene in Coronary Artery Dilation Disease

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

Introduction: The coronary artery dilatations disease (Coronary artery aneurysm/coronary artery ectasia) characterized by inappropriate coronary artery dilations. (c.894G>T) is a gene polymorphism that may decreases eNOS enzyme activity which increases the risk for coronary heart disease by affecting released (NO) molecules. One of the most researched variations in eNOS gene is c.894G>T polymorphism, which changes amino acid sequence at position 298 from Glu (GAG) to Asp (GAT), nevertheless, its role in Coronary dilatations disease still uncertain. Aim of study: To study correlation between the c.894G>T gene polymorphism and angiographically dilated coronary artery (CAA/CAE), as well as to determine whether there is any association between this polymorphism and atherosclerotic CAD. Methodology: A comparative study on 100 patients with acute coronary syndrome who underwent coronary angiography from December 2020 to June 2022. According to standard angiographic views and expert opinions, patients were divided as, 25 patients normal, 25 patients had only atherosclerotic coronary artery disease, 25 patients had dilated coronaries (CAA/CAE) without atherosclerosis and 25 patients had dilated coronaries with atherosclerotic coronary artery disease. The specific genetic PCR laboratory test were performed for eNOS SNPs (single nucleotide polymorphism) namely, 894G > T (Glu298Asp; rs 1799983), using Real-Time PCR.

NCT ID: NCT06001957 Completed - Coronary Aneurysm Clinical Trials

Whole Exome Sequencing in Coronary Artery Ectasia

Start date: March 23, 2022
Phase:
Study type: Observational

The goal of this observational study is to assess the role of the whole exome sequencing (WES) application in patients with giant coronary artery ectasia (CAE) with a high-risk of genetic background. The main question it aims to answer are: - the assessment of role of WES in CAE - the detection of novel pathogenic mutations associated with CAE development

NCT ID: NCT05410678 Completed - Clinical trials for Coronary Artery Ectasia

Safety And Efficacy Results of Percutaneous Renal Stent Implantation in Ectatic and Aneurysmatic Coronary Arteries

Start date: June 1, 2015
Phase: Phase 4
Study type: Interventional

The aim of this study was to evaluate the efficacy and safety of renal stents implanted in ectatic/aneurysmatic coronary arteries.

NCT ID: NCT04985773 Completed - Coronary Stenosis Clinical Trials

A Study to EXhibit Percutaneous Coronary Artery Dilatation With Non-Slip Element Balloon

EXPANSE-PTCA
Start date: December 17, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate safety and effectiveness of the Lacrosse NSE ALPHA coronary dilatation catheter during PCI in subjects with stenotic coronary arteries.

NCT ID: NCT03896321 Completed - Clinical trials for Coronary Artery Disease

Coronary Artery Ectasia in Elective Coronary Angiography : Predictors, Outcomes and Management

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

Coronary artery ectasia (CAE) is the diffuse dilatation of coronary artery. It is defined as a dilatation with a diameter of 1.5 times the adjacent normal coronary artery . Its prevalence ranges from 1.2%-4.9% with male to female ratio of 3:1 . Coronary ectasia likely represents an exaggerated form of expansive vascular remodelling (i.e. excessive expansive remodelling) in response to atherosclerotic plaque growth . CAE is more common in males. Hypertension is a risk Factor. Interestingly, patients with DM have low incidence of CAE. This may be due to down regulation of MMP with negative remodelling in response to atherosclerosis . Smoking appears to be more common in patients with CAE than in those with coronary artery disease (CAD). The angiographic classification for CAE (described by Markis et al.) categorizes the severity based on the extent of coronary arterial involvement: Type 1: Diffuse ectasia of 2-3 arteries; Type 2: Diffuse ectasia in one artery and localized in another; Type 3: Diffuse single arterial ectasia; Type 4: Localized or segmental ectasia . Stable angina is the most common presentation in patients with CAE . Patients with CAE without stenosis had positive results during treadmill exercise tests. ST-elevation myocardial infarction (MI) , non-ST elevation MI can occur from altered blood flow by distal embolization or occlusion of ectatic segment with thrombus. Medical management for CAE is a controversial area as there is lack of evidence based medicine, especially the role of antiplatelet versus anticoagulant agents. Aspirin was suggested in all patients because of coexistence of CAE with obstructive coronary lesions in the great majority of patients and the observed incidence of myocardial infarction, even in patients with isolated coronary ectasia .The role of dual anti platelet therapy has not been evaluated in prospective randomized studies. Based on the significant flow disturbances within the ectatic segments, chronic anticoagulation with warfarin as main therapy was suggested

NCT ID: NCT02563626 Completed - Clinical trials for Coronary Artery Aneurysm

Coronary Artery Aneurysm Registry

CAAR
Start date: September 2015
Phase:
Study type: Observational [Patient Registry]

International registry gathering patients with angiographically confirmed coronary aneurysm.

NCT ID: NCT02410083 Completed - Clinical trials for ANEURYSM CORONARY ARTERY

Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent

Start date: November 2012
Phase: Phase 4
Study type: Interventional

The purpose of this study in to evaluate efficacy and tolerability of Clopirin and clopidogrel with aspirin in Korean Patients with post-percutaneous coronary artery intervention.

NCT ID: NCT00132080 Completed - Clinical trials for Cardiovascular Diseases

Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network

Start date: December 2002
Phase: Phase 3
Study type: Interventional

The primary endpoint is coronary artery diameter, normalized for body surface area, 5 weeks after randomization. Secondary endpoints include duration of fever, CRP levels, and adverse events.

NCT ID: NCT00000520 Completed - Clinical trials for Cardiovascular Diseases

Prevention of Coronary Aneurysms in Kawasaki Syndrome

Start date: July 1985
Phase: Phase 2
Study type: Interventional

To test the efficacy of intravenous gamma globulin (IVGG) in preventing coronary artery aneurysms in children with Kawasaki Syndrome.